CJC-1295 Safety Questions: What Studies Report

Searches about CJC-1295 safety often ask a specific question — whether it raises blood pressure, whether it affects a particular organ, or whether it has been studied in a particular group of people. This page reports what the published literature contains, study by study, including the places where the honest answer is that no data were published. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, symptom or medication.

What CJC-1295 Is in the Published Literature: What Studies Report

CJC-1295 was described in the peer-reviewed literature as a growth hormone-releasing hormone (GHRH) analog built on the hGRF(1-29) fragment and linked by drug affinity complex (DAC) technology to circulating albumin. A 2005 Endocrinology paper characterised hGRF(1-29)–albumin bioconjugates in rats, reported that they activated the GRF receptor on the anterior pituitary, and identified CJC-1295 as the long-lasting analog among the conjugates tested. A 2006 study in the GHRH knockout mouse reported that once-daily administration normalized growth in that model. Neither of those papers was a human safety trial; both were pharmacology studies in animals.

Readers should note the regulatory backdrop: there is no approved CJC-1295 medicine, and the compound appears in the literature as an investigational analog and as a doping-control target rather than as a marketed product. That absence of an approval pathway is also why long-term safety datasets of the kind that accompany approved drugs do not exist for this molecule.

Human Trial Safety Findings: What Studies Report

The core human evidence comes from a 2006 Journal of Clinical Endocrinology & Metabolism report describing randomized, double-blind, placebo-controlled trials in healthy adults. In the escalating single-administration trial, researchers reported use of 30, 60, 125 and 250 µg/kg, and the repeated-administration trial reported 60 or 90 µg/kg weekly and 60 µg/kg every other week (PMID 16352683).

On pharmacodynamics, the study reported dose-dependent increases in mean plasma growth hormone of roughly 2- to 10-fold for six days or more, and IGF-1 increases of roughly 1.5- to 3-fold sustained for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days (PMID 16352683). On safety, the same report characterised CJC-1295 as safe and relatively well tolerated, particularly at the 30 and 60 µg/kg doses, and did not describe serious adverse events at the level of detail available in the published abstract.

Two limitations matter when that sentence is read as a safety statement. First, the trials enrolled healthy adults, not people with cardiovascular, metabolic or oncological conditions. Second, the exposure was short — single administrations and a small number of repeated administrations — so nothing in that report speaks to months or years of exposure.

Blood Pressure and Cardiovascular Measures: What Studies Report

This is the most common specific safety search, and it has a plain answer. None of the verified CJC-1295 papers reported blood pressure, heart rate, echocardiographic measures or cardiovascular events as a study outcome. The human trials reported hormone concentrations, pharmacokinetics and overall tolerability (PMID 16352683); a companion human analysis reported serum protein profile changes (PMID 19386527); and a further human study reported the pattern of growth hormone secretion under sustained stimulation (PMID 17018654). No blood pressure endpoint appears in any of them.

Because no published data exist, the literature supports neither the claim that CJC-1295 raises blood pressure nor the claim that it does not. Any statement in either direction on forums or product pages is extrapolation from general growth hormone physiology, not a finding from a CJC-1295 trial. Questions about cardiovascular risk in an individual belong with a licensed physician who can assess that person directly.

Growth Hormone Pulsatility and Axis Behaviour: What Studies Report

A recurring theoretical safety question is whether a long-acting GHRH analog flattens the normal pulsatile pattern of growth hormone release. A 2006 JCEM study addressed exactly that question and reported that pulsatile growth hormone secretion persisted during continuous stimulation by CJC-1295, alongside increased overall growth hormone secretion in the healthy adults studied. The study framed this as a characteristic of the analog's mechanism rather than as a clinical safety outcome, and it did not report organ-level endpoints.

Sustained IGF-1 elevation is the axis change most often discussed in relation to safety. The human trial reported IGF-1 remaining above baseline for a period of days after administration (PMID 16352683), but the published work did not follow participants long enough to examine any downstream consequence of prolonged elevation. That is a gap in the evidence, not a reassurance.

Serum Protein Changes: What Studies Report

A 2009 paper in Growth Hormone & IGF Research reported that activation of the GH/IGF-1 axis by CJC-1295 produced serum protein profile changes in normal adult subjects. Researchers presented this primarily as a biomarker and detection-relevant finding — a signature of axis activation — rather than as evidence of harm or of organ injury. The paper did not report adverse clinical events, and it did not assess kidney, liver or cardiac function as safety endpoints.

Animal Study Safety Reporting: What Studies Report

The animal literature in this verified set was designed to characterise pharmacology, not toxicity. The 2005 rat work reported receptor activation at the anterior pituitary and identified CJC-1295 as the longest-lasting of the GRF conjugates examined. The GHRH knockout mouse study reported that once-daily administration normalized growth in animals lacking endogenous GHRH. Neither paper was a formal toxicology study, and neither reported histopathology, blood pressure, tumour incidence or long-term survival outcomes.

Product Identity and Preparation Quality: What Studies Report

A safety issue that does appear directly in the literature concerns what is actually inside unlabelled preparations. A 2010 Drug Testing and Analysis report described the identification of CJC-1295 in an unknown pharmaceutical preparation, meaning analytical chemistry was required to establish the contents of a product that did not declare them. Researchers documented this as an analytical identification case. The wider implication reported in that literature is that the identity, purity and concentration of material circulating outside regulated manufacturing cannot be assumed from labelling.

Unsupervised Use Described in Online Communities: What Studies Report

A 2016 netnographic study in Substance Use & Misuse examined how women discussed CJC-1295 in online communities. The study reported on self-described practices, information-sharing and the sourcing of material outside clinical supervision. It was an observational analysis of internet discourse, so any effects or problems described within it were self-reported accounts rather than measured clinical outcomes, and the authors did not verify doses, products or medical histories. Researchers presented the work as a description of a user community, not as a safety trial.

Doping Control Context: What Studies Report

Two equine analytical papers indicate that CJC-1295 has been treated as a substance requiring detection in competition animals. A 2019 LC-MS/MS method paper described confirming CJC-1295 abuse in equine plasma samples, and a companion 2019 paper described an immuno polymerase chain reaction screen for CJC-1295 and other GHRH analogs in equine plasma. These were analytical method developments; neither reported physiological effects, adverse events or safety outcomes in horses.

Study-by-Study Summary Table

Populations With No Published CJC-1295 Data

The verified literature contains no trial data for several groups that commonly appear in safety questions:

• Pregnancy and breastfeeding: no study in this set enrolled pregnant or lactating participants.
• Children and adolescents: the human trials were conducted in adults (PMID 16352683).
• People with diabetes or impaired glucose tolerance: no glucose or insulin-sensitivity safety endpoint was reported in the verified human papers.
• People with active or prior cancer: no oncological outcome was studied or reported.
• People with cardiovascular, kidney or liver disease: no organ-specific safety endpoint appears in these reports.
• Older adults over long durations: the published human exposure was short.

Where no data exist, the correct description is uncertainty. It is not accurate to describe CJC-1295 as safe in these groups, and it is equally inaccurate to cite a specific published harm, because neither has been reported.

How to Read the Safety Evidence as a Whole

Three features define this evidence base. It is small: a handful of human papers, most from a single research programme in the mid-2000s. It is short: single and repeated administrations over weeks, not chronic dosing. And it is mechanistic: the primary outcomes were hormone concentrations, pharmacokinetics and secretory patterns (PMID 16352683; PMID 17018654), not clinical safety endpoints such as blood pressure, glucose regulation or organ function.

The remaining literature is analytical and observational: methods for detecting the compound in equine plasma (PMID 30938069, PMID 30489688), identification of the compound in an unlabelled preparation (PMID 21204297), and a qualitative study of online communities (PMID 26771670). None of those add clinical safety outcomes. Anyone weighing a personal health question should discuss it with a licensed physician; this page describes published research only and is not medical advice.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (Endocrinology, 2005)
• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (American Journal of Physiology. Endocrinology and Metabolism, 2006)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (Drug Testing and Analysis, 2010)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma (Drug Testing and Analysis, 2019)